These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 34035003)

  • 1. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
    Haberman RH; Herati R; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy SM; Neurath MF; Abramson SB; Schett G; Mulligan MJ; Scher JU
    Ann Rheum Dis; 2021 Oct; 80(10):1339-1344. PubMed ID: 34035003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
    Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU
    medRxiv; 2021 May; ():. PubMed ID: 34013285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination.
    Firinu D; Perra A; Campagna M; Littera R; Fenu G; Meloni F; Cipri S; Sedda F; Conti M; Miglianti M; Costanzo G; Secci M; Usai G; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L
    Clin Exp Med; 2022 Aug; 22(3):477-485. PubMed ID: 34741188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
    Mahil SK; Bechman K; Raharja A; Domingo-Vila C; Baudry D; Brown MA; Cope AP; Dasandi T; Graham C; Khan H; Lechmere T; Malim MH; Meynell F; Pollock E; Sychowska K; Barker JN; Norton S; Galloway JB; Doores KJ; Tree T; Smith CH
    Lancet Rheumatol; 2022 Jan; 4(1):e42-e52. PubMed ID: 34778846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study.
    Hitchon CA; Mesa C; Bernstein CN; Marrie RA; Card C; O'Brien SF; Kim J
    BMJ Open; 2023 May; 13(5):e071397. PubMed ID: 37253487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy.
    Firinu D; Fenu G; Sanna G; Costanzo GA; Perra A; Campagna M; Littera R; Locci C; Marongiu A; Cappai R; Melis M; Orrù G; Del Giacco S; Coghe F; Manzin A; Chessa L
    J Autoimmun; 2022 Jul; 131():102848. PubMed ID: 35714496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases.
    Udaondo C; Cámara C; Miguel Berenguel L; Alcobendas Rueda R; Muñoz Gómez C; Millán Longo C; Díaz-Delgado B; Falces-Romero I; Díaz Almirón M; Ochando J; Méndez-Echevarría A; Remesal Camba A; Calvo C
    Pediatr Rheumatol Online J; 2022 Aug; 20(1):64. PubMed ID: 35964130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.
    Shirata M; Ito I; Tanaka M; Murata K; Murakami K; Ikeda H; Oi I; Hamao N; Nishioka K; Hayashi Y; Nagao M; Hashimoto M; Ito H; Ueno H; Morinobu A; Hirai T
    Clin Exp Med; 2023 Dec; 23(8):4707-4720. PubMed ID: 37582911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence.
    Al-Haideri MT; Mannani R; Kaboli R; Gharebakhshi F; Darvishzadehdeldari S; Tahmasebi S; Faramarzi F; Cotrina-Aliaga JC; Khorasani S; Alimohammadi M; Darvishi M; Akhavan-Sigari R
    Transpl Immunol; 2023 Aug; 79():101858. PubMed ID: 37236514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
    Al-Janabi A; Ra A; Littlewood Z; Foulkes AC; Hunter HJA; Chinoy H; Moriarty CA; Hyrich KL; Limdi JK; Yiu ZZN; Griffiths CEM; Warren RB
    Br J Dermatol; 2023 Mar; 188(4):542-551. PubMed ID: 36695406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.
    Mahil SK; Bechman K; Raharja A; Domingo-Vila C; Baudry D; Brown MA; Cope AP; Dasandi T; Graham C; Lechmere T; Malim MH; Meynell F; Pollock E; Seow J; Sychowska K; Barker JN; Norton S; Galloway JB; Doores KJ; Tree TIM; Smith CH
    Lancet Rheumatol; 2021 Sep; 3(9):e627-e637. PubMed ID: 34258590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
    Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
    BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
    Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.
    Venerito V; Stefanizzi P; Fornaro M; Cacciapaglia F; Tafuri S; Perniola S; Iannone F; Lopalco G
    RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.
    Syversen SW; Jyssum I; Tveter AT; Tran TT; Sexton J; Provan SA; Mjaaland S; Warren DJ; Kvien TK; Grødeland G; Nissen-Meyer LSH; Ricanek P; Chopra A; Andersson AM; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Lund-Johansen F; Jørgensen KK; Goll GL
    Arthritis Rheumatol; 2022 Aug; 74(8):1321-1332. PubMed ID: 35507355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases.
    Cheung MW; Dayam RM; Shapiro JR; Law JC; Chao GYC; Pereira D; Goetgebuer RL; Croitoru D; Stempak JM; Acheampong L; Rizwan S; Lee JD; Jacob L; Ganatra D; Law R; Rodriguez-Castellanos VE; Kern-Smith M; Delgado-Brand M; Mailhot G; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Watts TH; Gingras AC
    J Immunol; 2023 Aug; 211(3):351-364. PubMed ID: 37326480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.
    Geldof J; Truyens M; Sabino J; Ferrante M; Lambert J; Lapeere H; Hillary T; Van Laethem A; de Vlam K; Verschueren P; Padalko E; Lobaton T; Vermeire S
    Front Immunol; 2023; 14():1126351. PubMed ID: 36936974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases.
    Hadjadj J; Planas D; Ouedrani A; Buffier S; Delage L; Nguyen Y; Bruel T; Stolzenberg MC; Staropoli I; Ermak N; Macraigne L; Morbieu C; Henriquez S; Veyer D; Péré H; Casadevall M; Mouthon L; Rieux-Laucat F; Chatenoud L; Schwartz O; Terrier B
    Ann Rheum Dis; 2022 May; 81(5):720-728. PubMed ID: 35022159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases.
    Sieiro Santos C; Calleja Antolin S; Moriano Morales C; Garcia Herrero J; Diez Alvarez E; Ramos Ortega F; Ruiz de Morales JG
    RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.